The authorisation may be subject to special conditions requiring the beneficiary of the authorisation to implement a plan for monitoring the efficacy and safety of the medicinal product, including the periodic collection of information concerning efficacy and adverse reactions and the transmission of this information to the Director General of the Agence nationale de sécurité du médicament et des produits de santé.